Aptose Biosciences (APS) Competitors C$1.58 -0.07 (-4.24%) As of 04:10 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesBuy This Stock APS vs. ABCN, EMC, FRX, BCT, IPA, TH, ONC, SCYB, COM, and NVHShould you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Oncolytics Biotech (ONC), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). These companies are all part of the "biotechnology" industry. Aptose Biosciences vs. Its Competitors VIVO Cannabis Emblem Fennec Pharmaceuticals BriaCell Therapeutics ImmunoPrecise Antibodies Theratechnologies Oncolytics Biotech Scythian Biosciences 138267 (COM.TO) Novoheart VIVO Cannabis (CVE:ABCN) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability. Do insiders & institutionals believe in ABCN or APS? 15.1% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, ABCN or APS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVIVO CannabisN/AN/AN/AN/AN/AAptose BiosciencesN/AN/A-C$154.69M-C$5.02-0.31 Do analysts rate ABCN or APS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VIVO Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aptose Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Does the media refer more to ABCN or APS? In the previous week, VIVO Cannabis' average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score. Company Overall Sentiment VIVO Cannabis Neutral Aptose Biosciences Neutral Is ABCN or APS more profitable? Aptose Biosciences' return on equity of 1,017.48% beat VIVO Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets VIVO CannabisN/A N/A N/A Aptose Biosciences N/A 1,017.48%-136.29% SummaryAptose Biosciences beats VIVO Cannabis on 5 of the 6 factors compared between the two stocks. Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APS vs. The Competition Export to ExcelMetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$68.03MC$137.08MC$5.76BC$6.37BDividend Yield0.39%3.74%4.41%6.72%P/E Ratio-0.313.8422.4073.11Price / SalesN/A4,053.59472.141,702.25Price / Cash1.6013.1937.7383.29Price / Book-1.7246.309.534.90Net Income-C$154.69M-C$90.99MC$3.26BC$301.20M7 Day Performance-8.14%0.61%2.11%1.36%1 Month Performance-30.40%3.58%5.12%1.96%1 Year Performance-90.42%197.78%31.25%28.87% Aptose Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APSAptose BiosciencesN/AC$1.58-4.2%N/A-91.5%C$68.03MN/A-0.3131Gap UpABCNVIVO CannabisN/AC$1.32+5.6%N/A+0.0%C$256.62MN/A0.00N/AGap UpEMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/AFRXFennec PharmaceuticalsN/AC$12.51-1.5%N/A+47.4%C$241.25MC$34.86M-211.9210BCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195IPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownTHTheratechnologiesN/AC$4.46+0.9%N/A+154.5%C$142.30MC$52.22M-50.49103ONCOncolytics Biotech1.7454 of 5 starsC$1.40+19.7%C$3.50+150.0%+7.8%C$107.90MN/A-3.9029Gap UpHigh Trading VolumeSCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/A Related Companies and Tools Related Companies ABCN Competitors EMC Competitors FRX Competitors BCT Competitors IPA Competitors TH Competitors ONC Competitors SCYB Competitors COM Competitors NVH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:APS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access